Lab21 Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Lab21 Ltd - overview
Established
2005
Location
Cambridge, -, UK
Primary Industry
Biotechnology
About
Lab21 Ltd specializes in providing digital solutions that enhance operational efficiency for businesses, focusing on website management and performance optimization. Lab21 Ltd, founded in 2005 by Emnet Mesfin, is headquartered in Cambridge, UK. The company has engaged in a total of 5 deals, with the most recent one occurring on May 27, 2014. During this round, Lab21 was acquired by NOVACYT Group for EUR 40 million.
The company has not undergone any notable pivots or changes in strategy since its inception. Lab21 Ltd offers a cloud-based platform for website management and performance optimization, designed to meet the needs of small to medium-sized enterprises across various industries. Released in 2017, the platform includes features such as automated backups and analytics integration, serving markets in North America, Europe, and parts of Asia with localized support. In the most recent year of 2018, Lab21 Ltd generated revenue of EUR 903,753.
30, with an EBITDA of EUR -7,577,110. 60. The company uses a subscription-based revenue model, fostering long-term client relationships through ongoing updates and support across various service tiers. Following its acquisition by NOVACYT Group in May 2014, Lab21 Ltd plans to leverage recent funding to enhance its product offerings and expand into new markets.
The company aims to launch new products designed to better serve its clients, though specific release dates have not been disclosed. Additionally, Lab21 intends to target further expansion in regions including North America and Europe by the end of 2024.
Current Investors
Excalibur Fund Managers, Kreos Capital, NMT Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Bioinformatics, Diagnostic, Medical & Imaging Laboratories, Medical Software
Website
www.lab21.com
Verticals
HealthTech
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Lab21 Ltd - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Lab21 Inc | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.